1998 Founding of “Invivo Diagnostica Entwicklungsgesellschaft mbH” in Berlin-Tempelhof. First commercial production of recombinant proteins.
1999 Relocation of the company to the Brandenburg biotech campus in Hennigsdorf. Construction of our first production and fermentation facilities.
2001 Development of proprietary serum-free media for cultivation of mammalian cells. Implementation of continuous high cell density fermentation and first production of monoclonal antibodies in 100 gram scale.
2004 Company renamed to InVivo Biotech Services GmbH. InVivo obtained ISO9001:2000 quality system.
2007 First large scale transient transfection using adherend HEK293 cells. Development of corresponding technology for suspension cells.
2008 Expansion of laboratory and production area to 900 m² (9700 ft²). Increase in fermentation capacity to ten independent bioreactor systems.
2010 Production and purification of the first 500 g batch. Implementation of a 100 L bioreactor.
2012 Increase in fermentation capacity to fourteen independent bioreactor systems.
2013 INVect, our novel polycationic reagent for transient transfection, is on market. Successful large scale transient transfection using suspension cells.
2016 Launch of InVivo’s Expression System for transient Transfection (InVEST).
InVEST comprises an optimized host cell line and a customized CD-ACF media platform tailored to support transfection and efficient suspension cultivation. In combination with our polycationic transfection reagent, state of the art vector design and large scale plasmid preparation, InVivo developed a high yielding expression system to meet customers’ needs. Please have a look on our new website for more information: www.transient-transfection.com
2016 With merger of ICI into InVivo, InVivo has a new operating facility in Berlin and is able to expand their service portfolio by immunoassay development and sample analysis.